Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone

Executive Summary

FDA may have to exit its drug review comfort zone and accept more trials outside the classic double-blind, placebo-controlled realm to promote more orphan drug development, industry and advocacy organizations told the agency

You may also be interested in...



Advocates Press For US FDA Rare Disease Center Of Excellence

Attorneys' proposal aims to better connect dispersed rare disease expertise within FDA's drug, biologic, and device centers through more leadership, new advisory committee.

US FDA's Rare Diseases Program Not Expected To Change With Drug Office Reorg

Reviewer expertise may be better leveraged in more focused roles, but basic tenets of rare disease program should not fundamentally change as part of proposed Office of New Drugs reorganization.

Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says

CDER Director Janet Woodcock says rare disease advocates should consider organizing patients to study a rare disease history and progression.

Related Content

Topics

UsernamePublicRestriction

Register

PS052400

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel